Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: amlodipine besylate; telmisartan

« Back to Dashboard
Amlodipine besylate; telmisartan is the generic ingredient in two branded drugs marketed by Lupin Ltd, Mylan Pharms Inc, Torrent Pharms Ltd, and Boehringer Ingelheim, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

There are forty-eight drug master file entries for amlodipine besylate; telmisartan. One supplier is listed for this compound.

Summary for Generic Name: amlodipine besylate; telmisartan

Tradenames:2
Patents:0
Applicants:4
NDAs:4
Drug Master File Entries: see list48
Suppliers / Packaging: see list4

Pharmacology for Ingredient: amlodipine besylate; telmisartan

Clinical Trials for: amlodipine besylate; telmisartan

Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension
Status: Completed Condition: Hypertension

CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)
Status: Completed Condition: Hypertension; Hyperlipidemia

Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine
Status: Completed Condition: Essential Hypertension; Hyperlipidemia

Telmisartan, Amlodipine and Combination in Healthy Subjects
Status: Completed Condition: Healthy

The Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan/Amlodipine
Status: Completed Condition: Hypertension; Hyperlipidemia

Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
Status: Recruiting Condition: Hypertension

CKD-828 (80/5mg) Pharmacokinetic Study
Status: Completed Condition: Hypertension

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
TWYNSTA
amlodipine besylate; telmisartan
TABLET;ORAL022401-003Oct 16, 2009RXNo<disabled><disabled>
Torrent Pharms Ltd
TELMISARTAN AND AMLODIPINE
amlodipine besylate; telmisartan
TABLET;ORAL202517-001Jan 8, 2014RXNo<disabled><disabled>
Lupin Ltd
TELMISARTAN AND AMLODIPINE
amlodipine besylate; telmisartan
TABLET;ORAL201586-004Jan 8, 2014RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: amlodipine besylate; telmisartan

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim
TWYNSTA
amlodipine besylate; telmisartan
TABLET;ORAL022401-001Oct 16, 20095,591,762<disabled>
Boehringer Ingelheim
TWYNSTA
amlodipine besylate; telmisartan
TABLET;ORAL022401-003Oct 16, 20095,591,762<disabled>
Boehringer Ingelheim
TWYNSTA
amlodipine besylate; telmisartan
TABLET;ORAL022401-002Oct 16, 20095,591,762<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc